Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 platelet inhibitor.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** To reduce the rate of thrombotic cardiovascular events (e.g., cardiovascular death, myocardial infarction, stroke) in patients with ACS, including unstable angina and non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI).
* **Post-Myocardial Infarction (MI):** To reduce the rate of thrombotic cardiovascular events in patients with a history of MI when treated with aspirin.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **Post-MI:**
* **Maintenance Dose:** 60 mg orally twice daily, initiated after 12 months of dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor. The duration of treatment with 60 mg twice daily should be individualized and based on patient risk.
## Pediatric Dosing
* Ticagrelor is not approved for use in pediatric patients. Safety and efficacy have not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is recommended for mild to moderate renal impairment. Use with caution in severe renal impairment; no specific dosing guidance is available.
* **Hepatic Impairment:** No dose adjustment is recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment; no specific dosing guidance is available.
## Contraindications
* Hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke (for use in ACS).
## Adverse Effects
* **Most Common:** Bleeding (including fatal and life-threatening), dyspnea, bradyarrhythmias.
* **Serious:** Significant bleeding events, ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor plasma concentrations. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease ticagrelor plasma concentrations.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Concomitant use with other antiplatelets or anticoagulants requires careful consideration and monitoring for bleeding.
* **Statins:** Concomitant use with simvastatin or rosuvastatin may increase statin exposure. Consider dose reduction of simvastatin or rosuvastatin.
* **Digoxin:** Ticagrelor may increase digoxin concentrations. Monitor digoxin levels and for signs of digoxin toxicity.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding (e.g., hematuria, melena, epistaxis, bruising, prolonged bleeding from cuts).
* **Bradycardia:** Monitor for symptoms of bradycardia (e.g., dizziness, fatigue, syncope). ECG monitoring may be indicated based on clinical assessment.
* **Renal and Hepatic Function:** Periodic monitoring may be considered, especially in patients with pre-existing impairment.
## Clinical Pearls
* Ticagrelor is dosed twice daily, unlike other P2Y12 inhibitors.
* The 90 mg dose is for the initial treatment of ACS. The 60 mg dose is for maintenance in post-MI patients or as extended DAPT.
* Patients taking ticagrelor should avoid aspirin doses above 100 mg.
* Discontinuation of ticagrelor may increase the risk of thrombotic events. If ticagrelor must be stopped, reinitiate as soon as possible.
* Ticagrelor can be taken with or without food.
***
*Please verify the current prescribing information for the most up-to-date details on dosing, indications, contraindications, and warnings.*
